CDE Granted LM-108 Breakthrough Therapy Designation for MSI-H/dMMR Solid Tumors

On February 8, 2025 LaNova Medicines Ltd. reported CDE has granted LM-108 (anti-CCR8 mAb) Breakthrough Therapy Designation (Press release, LaNova Medicines, FEB 8, 2025, View Source [SID1234656016]). This designation is for the treatment of patients with advanced solid tumors who have disease progression following immune checkpoint inhibitor treatment and are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!